CEO total pay
$5,772,848
Joseph Morrissey · 2025
Say on pay
78%
Latest disclosed shareholder vote
CEO pay ratio
CD&A79 to 1
Median employee: $6,097,395
Compensation committee
CD&ANot extracted
Per the latest proxy
Filings indexed: 2 · 2026 · 2025
Executive pay
What did they pay them?
From the Summary Compensation Table. Pay mix and YoY are computed from these rows.
| Executive | Role | TotalYoY | Pay mix | Salary | Stock | Cash incentive | Other |
|---|---|---|---|---|---|---|---|
Kevin Ali2025 compensation | Former Chief Executive Officer | $15,813,296↓ 8% | 85% at-risk | $1,088,462 | $10,251,989 | — | $1,222,846 |
Joseph Morrissey2025 compensation | Interim Chief Executive Officer | $5,772,848↑ 40% | 82% at-risk | $819,231 | $3,365,818 | $602,433 | $235,368 |
Matthew Walsh2025 compensation | EVP and Chief Financial Officer | $5,686,204↓ 1% | 80% at-risk | $919,231 | $3,036,171 | $532,800 | $235,504 |
Juan Camilo Arjona Ferreira, M.D.2025 compensation | EVP and Head of R&D and Chief Medical Officer | $3,822,487↑ 6% | 77% at-risk | $734,615 | $1,892,658 | $437,760 | $157,456 |
Rachel Stahler2025 compensation | EVP and Chief Digital | $3,551,619 | 76% at-risk | $706,923 | $1,734,932 | $411,840 | $147,924 |
Kirke Weaver2025 compensation | EVP, General Counsel | $3,542,975 | 76% at-risk | $676,923 | $1,734,932 | $394,560 | $186,560 |
Pay mix: base cash incentive equity other
CD&A excerpt
Compensation discussion & analysis
Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.
Read the full CD&A on SEC.gov ↗
Peer comparison
Who they benchmark against
Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.
2025 Compensation Peer Group
18 members · 5 in ProxyMiner
A · AGILENT TECHNOLOGIES, INC.EW · Edwards Lifesciences CorpPRGO · PERRIGO Co plcAVTR · Avantor, Inc.ELAN · Elanco Animal Health IncREGN · REGENERON PHARMACEUTICALS, INC.BHC · Bausch Health Companies Inc.RVTY · REVVITY, INC.BAX · BAXTER INTERNATIONAL INCINCY · INCYTE CORPVERX · Vertex, Inc.BIIB · BIOGEN INC.ISRG · INTUITIVE SURGICAL INCVTRS · Viatris IncBSX · BOSTON SCIENTIFIC CORPIQV · IQVIA HOLDINGS INC.ZTS · Zoetis Inc.JAZZ · Jazz Pharmaceuticals plc
Governance
Policy guardrails
hedging
prohibited
“As part of our Insider Trading Policy, we prohibit directors and specified key employees, including officers, from engaging in short sales, publicly traded options, hedging transactions and pledging of Organon common sto…”
pledging
prohibited
“As part of our Insider Trading Policy, we prohibit directors and specified key employees, including officers, from engaging in short sales, publicly traded options, hedging transactions and pledging of Organon common sto…”
clawback
present
“Clawback Policy”)”
stock ownership guidelines
present
“Executive Stock Ownership Guidelines”
change in control
Potential Payments Upon Termination or Change in Control
“Potential Payments Upon Termination or Change in Control”
compensation consultant
independent
“Independent Compensation Consultant”
compensation committee
FW Cook did not attend any meetings or recommend the amount or form of executive compensation to the Talent Committee during 2025.
“FW Cook did not attend any meetings or recommend the amount or form of executive compensation to the Talent Committee during 2025.”
Performance markers
Metric facts
revenue
$6.216 billion
“** * The actual amounts for Revenue and Adjusted EBITDA were adjusted as described in the sections below. ** Result shown is rounded to the nearest whole percentage. Revenue In establishing the Revenue target for 2025, t…”
annual incentive payout
45%
“· Modified the relative weightings of the 2026 Company Scorecard design while maintaining adjusted EBITDA, constant currency revenue, and the non-financial strategic priorities as the core annual cash incentive plan meas…”
time equity mix
—
“PSU awards are converted to time-based RSU awards upon a change in control, based on target performance.”
say on pay
78%
“Shareholder Engagement and Results of 2025 Say on Pay Vote”
ceo pay ratio
79 to 1
“compensation of our median employee, calculated in the same manner as we calculate total annual compensation for purposes of the Summary Compensation Table, was $77,368. The total annualized compensation for our Interim …”
median employee compensation
$6,097,395
“in the same manner as we calculate total annual compensation for purposes of the Summary Compensation Table, was $77,368. The total annualized compensation for our Interim CEO, adjusted from 2025 Summary Compensation Tab…”
Ask
Anything about Organon & Co.’s 2026 proxy
Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.
Loading the Ask interface…